

Abstract Number: 4CPS-113

DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS

García Moreno FJ, González-Haba E, Sánchez Fresneda MN, García Martín E, García Sánchez S, Marzal Alfaro B, Collado Borrell R, Mur Mur A, Herranz Alonso A, Sanjurjo Sáez M.

Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IISGM). Madrid, España

OBJECTIVES

Background: The development of checkpoint inhibitors-based immunotherapy has completely changed the therapeutic approach of metastatic melanoma (MM). In parallel, the research activity about this tumor continues at a very high level through a large number of active industry-funded clinical trials.

Objective: To estimate the cost saving in MM therapy attributable to clinical trials (CT) in a university tertiary hospital during the period 2016-2017.


METHODS

- ✓ Observational, retrospective study that takes into account **sponsored CT**.
- ✓ The **standard therapy (ST) comparison** was chosen for each trial according to the Investigator's brochure and NCCN (National Comprehensive Cancer Network) Guidelines.
- ✓ Duration of ST -> equated with the **time of permanence** of the subject **in the trial**
 - Oral ST: days of treatment
 - Intravenous ST: complete cycles received
- ✓ Dose of ST -> established according to **body surface area** or **weight at recruitment** to trial.
- ✓ Costs of ST -> estimated using **hospital-specific tender price on 1 January** of each year. It was considered a maximum reuse of vials.

Limitation: We did not consider the cost of working in aseptic conditions and the cost of administering the drugs.

RESULTS


CT for MM : 14
(≥ 1 patient treated in our center between 2016-2017)



47 PATIENTS TREATED

ESTIMATED COST SAVING


2016: 809,630 €
2017: 804,349 €
(34.340 €/patient)



Standard therapy				
ST considered: Therapeutic group	Number of CT	Patients treated	Estimated cost saving (€)	Ratio between savings and spendings on MM 2016-2017 (%)
Immunotherapy (ATC: L01XC)	5	34	1,195,294	99.4
BRAF/MEK inhibitors (ATC: L01XE)	4	7	417,565	44.2
Alkylating agents (ATC: L01A)	2	6	1,120	-

CONCLUSIONS

- ✓ CT using Investigational Medicinal Products provided by the sponsor give a considerable saving for our healthcare system within a context of clinical research and innovation.
- ✓ This saving remained constant between 2016 and 2017 in our study.



<http://www.eahp.eu/24-4CPS-113>

